52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Biogen To Acquire Novel Clinical Stage Asset With Application In Alzheimer’S Disease And Parkinson’S Disease From Pfizer Inc.
Banner Life Sciences Receives Favorable Ruling Against Biogen In Patent Infringement Challenge
Invitae - Behind The Seizure Program Expands Access To Genetic Testing For Children
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
225 Binney St
Stelios B. Papadopoulos
Independent Chairman of the Board
Chief Executive Officer, Director
Jeffrey D. Capello
Chief Financial Officer, Executive Vice President
Chief Human Resource Officer, Executive Vice President
Susan H. Alexander
Executive Vice President, Chief Legal Officer and Secretary
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Swiss drugmaker Roche plans to price its oral spinal muscular atrophy drug (SMA) risdiplam aggressively to challenge two of the world's most expensive medicines, Biogen's Spinraza and Novartis's gene therapy Zolgensma.
Biogen Inc said on Friday it would discontinue the development of its experimental therapy for a rare brain disease after the treatment failed a mid-stage trial, the latest setback in attempts to develop a therapy for the disorder.
Biogen Inc said on Friday it would discontinue the development of its experimental therapy for a rare brain disease after it failed a mid-stage trial.
Biogen Inc on Thursday laid out more data on its experimental Alzheimer's drug that raised no major safety alarms but also offered little compelling evidence the drug, once declared a failure, actually works.
Biogen Inc on Thursday presented new data on its experimental Alzheimer's drug aducanumab that eased concerns raised by some experts but still left many questions unanswered as the company made its case about why it plans to seek U.S. approval after declaring the drug a...
Biogen Inc on Thursday presented new data from on its experimental Alzheimer's drug aducanumab showing that no patients in a high-risk group that were genetically predisposed to get Alzheimer's died while taking the high dose of the drug, which had been a key concern.
Novartis research head Jay Bradner said on Thursday the Swiss drugmaker is focusing efforts against spinal muscular atrophy (SMA) on gene therapy Zolgensma and retreating from oral therapy like its molecule LMI070, also called branaplam.
Biogen Inc, looking to win over skeptics and health regulators, later on Thursday will present highly anticipated data on its experimental Alzheimer's drug aducanumab, which the U.S. biotech company had declared a failure earlier this year.
Roche expects its risdiplam medicine for spinal muscular atrophy to get U.S. approval by next May, the Swiss drugmaker said on Monday, as it takes on Novartis and Biogen in the lucrative rare disease area.
Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function in a key study.
Roche's bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study.
The U.S. Food and Drug Administration on Wednesday approved Biogen Inc's new oral drug to treat multiple sclerosis, offering the drugmaker some relief as its core franchise faces patent challenges.
Biogen Inc and partner Alkermes Plc said on Wednesday that the U.S. Food and Drug Administration approved their oral drug to treat multiple sclerosis.
Biogen Inc <BIIB.O> revived plans on Tuesday to seek U.S. approval for Alzheimer's treatment aducanumab, surprising investors and saying data from more patients in two discontinued studies showed the drug reduced the decline of patients.
Wall Street opened higher on Tuesday after a batch of upbeat earnings reports eased concerns over domestic growth and the fallout from the U.S.-China trade war, while a surge in Biogen boosted the healthcare sector.
Drugmaker Biogen Inc <BIIB.O> reported a 7.1% rise in third-quarter profit on Tuesday, boosted by higher demand for its rare muscle disease drug, Spinraza.
Drugmaker Biogen Inc said on Tuesday it was planning to file for U.S. regulatory approval for its Alzheimer's treatment aducanumab after fresh analysis of its clinical trial showed promise.
Biogen Inc and Eisai Co Ltd are abandoning two late-stage trials for their Alzheimer's treatment in a widely anticipated move that comes months after the companies scrapped trials of another drug for the memory-robbing disease.
Biogen Inc and partner Eisai Co Ltd said on Friday they would abandon two late-stage trials testing their experimental treatment, elenbecestat, for patients with early Alzheimer's disease.
Biogen Inc <BIIB.O> reported better-than-expected second quarter profit and raised its 2019 earnings forecast on Tuesday, driven by higher sales of its top-selling multiple sclerosis drug Tecfidera and lower taxes.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.